Managing renal complications in multiple myeloma.

about

Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit.

P2860

Q41080072-B11AD6F1-7BBA-4D2C-A1BB-DC10A467EE73

P2860

Managing renal complications in multiple myeloma.

Item

http://www.wikidata.org/entity/Q38900024

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Managing renal complications in multiple myeloma.

@en

type

Item

label

Managing renal complications in multiple myeloma.

@en

prefLabel

Managing renal complications in multiple myeloma.

@en

P1476

Managing renal complications in multiple myeloma.

@en

P2093

Despoina Fotiou

http://www.w3.org/2001/XMLSchema#string

P2860

Novel agents for multiple myeloma to overcome resistance in phase III clinical trials

Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

P304

839-850

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474086.2016.1210003

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Efstathios Kastritis

P577

2016-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27426872

http://www.w3.org/2001/XMLSchema#string

Managing renal complications in multiple myeloma.

about

P2860

P2860

Managing renal complications in multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698